{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wilson AM"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)"],"pagination":["2282-2291"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7724556"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["324(22)"],"pubmed_abstract":["<h4>Importance</h4>Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options. Patients with IPF have altered lung microbiota, with bacterial burden within the lungs associated with mortality; previous studies have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole).<h4>Objective</h4>To determine the efficacy of co-trimoxazole in patients with moderate and severe IPF.<h4>Design, setting, and participants</h4>Double-blind, placebo-controlled, parallel randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (forced vital capacity ≤75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient visit) and April 2019 (las"],"journal":["JAMA"],"pubmed_title":["Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial."],"pmcid":["PMC7724556"],"funding_grant_id":["MC_PC_14145","CS-2013-13-017"],"pubmed_authors":["Chilvers ER","Fraser W","Cahn T","Swart AM","Stirling S","Maher TM","Hammond M","Whyte M","EME-TIPAC team","Thickett DR","Parfrey H","Clark AB","Wilson AM","Livermore DM"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.","description":"<h4>Importance</h4>Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options. Patients with IPF have altered lung microbiota, with bacterial burden within the lungs associated with mortality; previous studies have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole).<h4>Objective</h4>To determine the efficacy of co-trimoxazole in patients with moderate and severe IPF.<h4>Design, setting, and participants</h4>Double-blind, placebo-controlled, parallel randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (forced vital capacity ≤75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient visit) and April 2019 (las","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-05-31T22:20:36.637Z","creation":"2025-05-31T22:20:36.637Z"},"accession":"S-EPMC7724556","cross_references":{"pubmed":["33289822"],"doi":["10.1001/jama.2020.22960"]}}